Literature DB >> 8435410

The EP2 receptor is the predominant prostanoid receptor in the human ciliary muscle.

T Matsuo1, M S Cynader.   

Abstract

Prostaglandins can reduce intraocular pressure by increasing uveoscleral outflow. We have previously demonstrated that the human ciliary muscle was a zone of concentration for binding sites (receptors) for prostaglandin F2 alpha and for prostaglandin E2. Here, we try to elucidate the types of prostanoid receptors in the ciliary muscle using competitive ligand binding studies in human eye sections and computer assisted autoradiographic densitometry. Saturation binding curves showed that the human ciliary muscle had a large number of binding sites with a high affinity for prostaglandin E2 compared with prostaglandin D2 and F2 alpha. The binding of tritiated prostaglandin E2 and F2 alpha in the ciliary muscle was displaced most effectively by prostaglandin E2 and 11-deoxy prostaglandin E1 (a selective EP2 prostanoid receptor agonist), whereas the binding of prostaglandin D2 was displaced most effectively by prostaglandin E2 and D2. These results indicate that the dominant prostanoid receptor in the human ciliary muscle is the EP2 subclass and that there is also a small number of DP receptors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8435410      PMCID: PMC504442          DOI: 10.1136/bjo.77.2.110

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  26 in total

1.  Prostaglandin F2 alpha binding to bovine ocular and synthetic melanins in vitro.

Authors:  P Aula; T Kaila; R Huupponen; L Salminen; E Iisalo
Journal:  Pharmacol Toxicol       Date:  1989-08

2.  Prostaglandin F2 alpha-isopropylester eye drops: effect on intraocular pressure in open-angle glaucoma.

Authors:  J Villumsen; A Alm; M Söderström
Journal:  Br J Ophthalmol       Date:  1989-12       Impact factor: 4.638

3.  Maintained reduction of intraocular pressure by prostaglandin F2 alpha-1-isopropyl ester applied in multiple doses in ocular hypertensive and glaucoma patients.

Authors:  C B Camras; E C Siebold; J S Lustgarten; J B Serle; S C Frisch; S M Podos; L Z Bito
Journal:  Ophthalmology       Date:  1989-09       Impact factor: 12.079

4.  Prostanoid-induced blood-aqueous barrier breakdown in rabbits involves the EP2 receptor subtype.

Authors:  C E Protzman; D F Woodward
Journal:  Invest Ophthalmol Vis Sci       Date:  1990-11       Impact factor: 4.799

5.  Biochemical characterization and autoradiographic localization of [3H]PGE2 binding sites in rat kidney.

Authors:  L O Eriksson; B Larsson; K E Andersson
Journal:  Acta Physiol Scand       Date:  1990-07

6.  EP3, but not EP2, FP, or TP prostanoid-receptor stimulation may reduce intraocular pressure.

Authors:  L D Waterbury; R M Eglen; G F Faurot; G F Cooper
Journal:  Invest Ophthalmol Vis Sci       Date:  1990-12       Impact factor: 4.799

7.  Prostaglandin E2 binding sites in bovine iris-ciliary body.

Authors:  P Bhattacherjee; S Csukas; C A Paterson
Journal:  Invest Ophthalmol Vis Sci       Date:  1990-06       Impact factor: 4.799

8.  Characterization of the prostanoid receptor profile of enprostil and isomers in smooth muscle and platelets in vitro.

Authors:  R M Eglen; R L Whiting
Journal:  Br J Pharmacol       Date:  1989-12       Impact factor: 8.739

9.  Studies on the ocular pharmacology of prostaglandin D2.

Authors:  D F Woodward; S B Hawley; L S Williams; T R Ralston; C E Protzman; C S Spada; A L Nieves
Journal:  Invest Ophthalmol Vis Sci       Date:  1990-01       Impact factor: 4.799

10.  Localisation of prostaglandin F2 alpha and E2 binding sites in the human eye.

Authors:  T Matsuo; M S Cynader
Journal:  Br J Ophthalmol       Date:  1992-04       Impact factor: 4.638

View more
  1 in total

1.  Pharmacology and autoradiography of human DP prostanoid receptors using [(3)H]-BWA868C, a DP receptor-selective antagonist radioligand.

Authors:  N A Sharif; G W Williams; T L Davis
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.